MARCH 19th, 2026
1. How Liver Function Defines Real-World Outcomes with Atezolizumab–Bevacizumab in uHCC
L. Stella, A. Gasbarrini, M. Pallozzi, L. Cerrito, C. Hollande, H. Fakouri, F.R. Ponziani, M. Bouattour
Rome, Clichy (France)
2. Chronic exposure to Bisphenol A triggers trained immunity-related pathways and innate remodeling in the pathogenesis of Metabolic dysfunction-associated steatotic liver disease (MASLD)
M. Dallio, M. Romeo, F. Di Nardo, A. Silvestrin, G. Senese, C. Napolitano, G. Martinelli), L. Di Puorto, A. Coppola, A. Federico
Naples
3. Prolonged Intake of Bicarbonate-Sulfate-Calcium-Magnesium Mineral Water Improves MASLD Outcomes via Modulation of Gut Barrier, Inflammation, and Oxidative Stress
M. Dallio, C. Napolitano, M. Romeo, F. Di Nardo, P. Vaia, C. Basile, G. Martinelli, S. Olivieri, L.M. Vitale, A. Federico
Naples
4. A head-to-head comparison of MAFLD and MASLD diagnostic criteria in estimating the risk of hepatocellular carcinoma (HCC) in HCV patients achieving sustained virological response
F. Di Nardo, M. Dallio, M. Romeo, C. Napolitano, P. Vaia, C. Basile, A. Scafuri, L.M. Vitale, M. Niosi, A. Federico
Naples
5. Baseline anti-mitochondrial antibody titre in addition to gamma-glutamyltranspeptidase and alanine-aminotransferase serum levels anticipate future primary biliary cholangitis development
D. Bitetto, C. Fabris, E. Fornasiere, E. Fumolo, E. Garlatti Costa, S. Cmet, P. Toniutto
Udine
6. Hepatic antifibrotic response by fibrogenesis markers in in patients with MASLD undergoing a 6-month randomized dietary trial
A. Armandi, R. Surabattula, D. J. Leeming, G.P. Caviglia, M. Guariglia, C. Rosso, E. Dileo, F. Bioletto, I. Goitre, V. Ponzo, F. Saba, K. Gjini, D.G. Ribaldone, S. Myneni, S. Bo, D. Schuppan, E. Bugianesi
Turin, Mainz (Germany), Herlev (Denmark), Boston (USA)
7. Involvement of the hERG1 potassium channel in cholangiocarcinoma cell biology
G. Alla Viligiardi, C. Duranti, C. Capitani, R. Colasurdo, T. Lottini, P. Ostano, A. Tani, J. Iorio, D. Nosi, D. Bani, A. Arcangeli, C. Raggi, E. Frediani, F. Margheri, M. Pastore, F. Marra, L. Maggi, A. Vanni, D. Guasti
Florence, Biella
8. Portal–Peripheral miRNA Signature Reveals a Chronic Pro-Inflammatory Trap in the Portal District linked to local Increased Endothelial NLRP3 Inflammasome Activity in Cirrhosis
K. Ferdinande, A. Zanetto, M. Carron, G. Barbiero, M. Battistel, S. Groff, S. Shalaby, R. Cardin, M. Senzolo
Padua, Barcelona (Spain)
9. PNPLA3 p.I148M variant affects lipid droplets number and composition in patient-derived liver organoids
E. Casirati, A. Cherubini, L. Cerami, F. Carli, D. Dondossola, A. Gastaldelli, D. Prati, L. Valenti
Milan, Pisa
10. Periportal immune niches shaping intrahepatic CD8+ T cells immunity
F. Andreata, E. Pensieri, C. Laura, M. Genua, D.L. Pietro, E. Bono, F. Iannucci, G. Eschillo, L. Giustini, C. Perrucchini, P. Delfino, C. Beccaria, L. Guidotti, M. Iannacone
Milan
11. An ultrasound/elastography screening experience for metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a High-Risk Population: prevalence and factors associated with MASLD and liver Fibrosis
F. Gabrielli, G. Piazza, S. Lugari, A. Cavicchioli, C. Felicani, A. Rudilosso, M. Bondi, C. Valenti, L. Valerio, C. Pacchioni, C. Greco, D. Santi, G. Spaggiari, M. Simoni, F. Carubbi, L. Bertarini, F. Pellati, P. Andreone, P. Ventura, F. Nascimbeni
Modena
12. Referral strategies in intermediate-risk FIB-4 patients: can longitudinal monitoring reduce FibroScan® use without missing advanced fibrosis?
K. Gjini, G.P. Caviglia, A. Armandi, M. Guariglia, E. Dileo, F. Saba, E. Bugianesi
Turin
13. Neurofilament Light Chain Proteins are a sensitive biomarker of neuronal damage in hepatic encephalopathy
C. Asero, F. Polito, M. S. Franzè, A. Battaglia, C. Ligresti, T. Maltese, M. Aguennouz, V. Macaione, I. Cacciola
Messina, Palermo
14. Predicting early progression in advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab: a multimodal deep learning approach
C. Celsa, S. Contino, R. Cannella, R. Ciccia, G. Crescimanno, L. Cruciata, S. Restuccia, G. Giusino, G. Cusimano, S. Calascibetta, A. Quartararo, G. Cabibbo, G. Cirrincione, R. Pirrone, C. Cammà
Palermo, Amiens (France)
15. Multimodal Deep Learning Model for BCLC Staging of Hepatocellular Carcinoma: Integration of Radiological Imaging and Clinical Data
C. Celsa, S. Contino, R. Cannella, M. Salvato, L. Cruciata, S. Restuccia, G. Giusino, G. Cusimano, S. Calascibetta, A. Quartararo, G. Cabibbo, G. Cirrincione, R. Pirrone, C. Cammà
Palermo, Amiens (France)
16. Deep Learning for Automated Classification of Liver Tumours on Digitalized Liver Biopsies: An Unsupervised and Semi-Supervised Approach
C. Celsa, A. Sparacino, S. Contino, A. Quattrocchi, T. Halimi, S. Messaoudi, L. Cruciata, G. Cabibbo, R. Pirrone, V. Calvaruso, A. Fagiolini, G. Cirrincione, D. Cabibi, C. Cammà
Palermo, Amiens (France)
17. Alcohol Use and Communication Gaps in Autoimmune Liver Diseases: Insights from an Online Patient Survey
M. Delle Monache, V. Ramundo, M. Delle Monache, C. Conigliani, F. Pascucci
Rome
18. Predicting The Best Potential Treatment By Artificial Intelligence For Patients Affected By Hepatocellular Carcinoma: Development Of An “augmented” multidisciplinary board
S. Famularo, O. Cicerone, F. Milana, A. Vitale, M. Maestri, F. Ardito, U. Cillo, F. Giuliante, G. Torzilli, F. Trevisani, E. Giannini
Rome, Pavia, Rozzano (MI), Padua, Bologna, Genoa
19. Prospective comparison of Viscoelastic Coagulation Monitor (VCM) and Rotational Thromboelastometry (ROTEM) in the assessment coagulation of cirrhosis
E. Pinto, F. Gerli, C. Bulato, E. Campello, K. Ferdinande, A. Ferrarese, M. Gambato, G. Germani, F. P. Russo, P. Burra, P. Simioni, M. Senzolo, A. Zanetto
Padua
20. Predicting Decompensation in Advanced HCC on Immunotherapy: The ARTE Score
L. Canova, E. Alimenti, L. Argiento, F. Tovoli, G. Cabibbo, F. Marra, C. Vivaldi, A. Dalbeni, F.R. Ponziani, A. Palloni, S. Lonardi, L. Rimassa, L. Lani, P. Federico, G. Svegliati-Baroni, L. Ielasi, C. Mazzarelli, S. De Lorenzo, R. Sacco, P. Toniutto, M. Iavarone
Milan, Bologna, Palermo, Florence, Pisa, Verona, Rome
21. Dynamics of thrombin generation predict thrombo-hemorrhagic events in cirrhosis: a prospective cohort study
A. Zanetto, A. Zanetto, R.A.L. Willems, E. Campello, J. Konings, C. Bulato, M. Kramer, M. Roest, F.P. Russo, M. Senzolo, P. Burra, H. ten Cate, J. de Vos-Geleen, B. de Laat, P. Simioni
Padua, Maastricht (The Netherlands), Mainz (Germany)
22. Physical frailty is the most important predictor of early mortality in hospitalized patients with decompensated cirrhosis
F. D’Arcangelo, L.M. Vivian, A. Ferrarese, M. Gambato, G. Germani, M. Senzolo, F. P. Russo, P. Burra, A. Zanetto
Padua
23. Porto-sinusoidal vascular disorder and sinusoidal obstructive syndrome in patients treated with thiopurines: a systematic review
E.N. Lynch, A. Curto, M. Tanturli, R. G. Iamello, E. Monaco, M. Vanni, T. Mello, T. Innocenti, G. Dragoni, A. Galli
Florence
24. Long-term real-life experience of semaglutide in a monocentric cohort with type 2 diabetes and metabolic dysfuction-associated steatotic liver disease (MASLD)
G. Petralli, A. Salvati, S. Cappelli, L. Surace, L. De Rosa, F. Damone, D. Tricò, A. Solini, M.R. Brunetto
Pisa
25. EUS-guided direct portal pressure, clinically significant portal hypertension and spleen stiffness: diagnostic and prognostic integration in a prospective cohort
F. Martini, L. Salvi, M. Dalla Bella, A. Alessandrini, D. Balducci, M. Montori, L. Maroni, M. Marzioni, A. Benedetti, G. Tarantino
Ancona
26. Brief Alcohol Counseling in Steatotic Liver Disease: A Single-Center Observational Study of Six-Month Changes in Alcohol Use, Noninvasive Liver Metrics, and Quality of Life
E.N. Lynch, A. Curto, G. Bianchi, M. Tanturli, R.G. Iamello, E. Monaco, M. Vanni, T. Mello, T. Innocenti, G. Dragoni, A. Galli
Florence
27. A Comparative Outcome and Safety Analysis of Lenvatinib Versus Sorafenib in Hepatocellular Carcinoma recurring after Liver Transplantation
M. Sagasta, E. Alimenti, C. Mazzarelli, M. De Giorgio, F. Villa, C. Dibenedetto, D. Costantino, F. Tosi, M. Orlando, L. Cesarini, S. Fagiuoli, M. Iavarone, P. Lampertico
Milan, Bergamo
28. Progressive decline of HBcrAg levels in patients with chronic hepatitis delta long-term treated with bulevirtide monotherapy
E. Degasperi, F. Facchetti, D. Sambarino, . Scholtes, B. Testoni, S. Uceda Renteria, M.P. Anolli, C. Charre, M. L. Plissonnier, R. Perbellini, A. Callegaro, M. Levrero, F. Zoulim, P. Lampertico
Milan, Lyon (France), Paris (France)
29. The effectiveness and safety of bulevirtide monotherapy are similar in chronic hepatitis delta patients with and without cirrhosis: results from the prospective multicenter d-shield study
M.P. Anolli, E. Degasperi, G. D’Offizzi, A. Rianda, A. Loglio, M. Viganò, A. Ciancio, Y. Troshina, M.R. Brunetto, B. Coco, S. Zaltron, A. Cambianica, M. Milella, E. Rosselli Del Turco, L. Turco, L. Sarmati, M. Tamè, P. Toniutto, A. Gasbarrini, L. Marinaro, F. P. Russo, A. Gori, I. Maida, A. Federico, T.A. Santantonio, R. Bruno, E. G. Giannini, I. Cacciola, F. Morisco, A. Mangia, S. De Nicola, A. Romano, M. Maracci, B. Pinchera, S.L. Crocè, F. Pileri, R. Zampino, M. Persico, P. Pozzoni, A. Pan, A. Pellicelli, N. Coppola, M. Tonnini, E. Grassi, A. Soria, P. Caraceni, G. Svegliati Baroni, I. Arena, V. Esposito, P. Vitiello, M. Puoti, P. Lampertico
Milan, Rome, Bergamo, Turin, Pisa, Brescia, Bari, Bologna, Udine, Padua, Sassari, Naples, Foggia, Pavia, Genoa, Messina, San Giovanni Rotondo (FG), Rozzano (MI), Ancona, Trieste, Modena, Baronissi (SA), Lecco, Cremona, Varese, Monza, Rho (MI)
30. Long-term virological and clinical outcomes in patients with hdv-related cirrhosis treated with bulevirtide monotherapy for up to 4 years (Save-D Study)
E. Degasperi, M. P. Anolli, D. Sambarino, M. Borghi, R. Perbellini, L. Gheorghe, M. Chitul, C. Schramm, H. Schmidt, M. Jachs, T. Reiberger, I. Carey, K. Agarwal, M. Buti, A. Palom, J. Vienneau, M. Tang, G. D’Offizi, F. di Maria, C. Zöllner, F. Tacke, C. Dietz-Fricke, H. Wedemeyer, M. Papatheodoridi, G. Papatheodoridis, F. Van Bömmel, S. Lens, M.R. Brunetto, M. Cardoso, A. Federico, E. Rosselli Del Turco, M. Meszaros, A. Ciancio, Á. Giráldez-Gallego, F. Zoulim, S. Aleman, N. Semmo, S. Metiver, A. Mangia, M. N. Hilleret, U. Merle, M. Viganò, T. A. Santantonio, N. Coppola, A. Pellicelli, J. Foucher, B. Roche, X. Causse, L. D’Alteroche, J. Dumortier, N. Ganne, F. Heluwaert, I. Ollivier, D. Roulot, I. Rosa, F. Pilleri, M. Maracci, M. Tonnini, J. P. Arpurt, K. Barange, E. Billaud, S. Pol, A. Gervais, A. Minello, M. Puoti, P. Lampertico
Milan, Bucharest (Romania), Essen (Germany), Vienna (Austria), London (UK), Barcelona (Spain), Calgary (Canada), Rome, Berlin (Germany), Hannover (Germany), Athens (Greece), Leipzig (Germany), Pisa, Amadora (Portugal), Naples, Bologna, Montpellier (France), Turin, Sevilla (Spain), Lyon (France), Stockholm (Sweden), Bern (Switzerland), Toulouse (France), San Giovanni Rotondo (FG), Grenoble (France), Heidelberg (Germany), Bergamo, Foggia, Bordeaux (France), Villejuif (France), Tours (France), Bobigny (France), Annecy (France), Caen (France), Créteil (France), Modena, Ancona, Avignon (France), Toulouse (France), Nantes (France), Paris (France), Dijon (France)
31. Systemic inflammatory markers predict overall survival and therapeutic response in immunotherapy-treated hepatocellular carcinoma
A. Rocco, C. Sgamato, F. Giordano, D. Angrisani, M. R. Attanasio, M. Guarracino, R. Tortora, G.G. Di Costanzo
Naples
32. Improvement in 3 noninvasive tests through 144 weeks of bulevirtide monotherapy in patients with chronic hepatitis delta with and without virologic response
M. Brunetto, S. Aleman, P. Andreone, P. Bogomolov, V. Chulanov, N. Geyvandova, V. Morozov, O. Sagalova, T. Stepanova, A. Lichtman, R.C. Mercier, D. Manuilov, M. Li, J. Schulze zur Wiesch, S. Zeuzem, H. Wedemeyer, P. Lampertico
Pisa, Stockholm (Sweden), Modena, Moscow (Russian Federation), Stavropol (Russian Federation), Samara (Russian Federation), Chelyabinsk (Russian Federation), Foster City (USA), Hamburg (Germany), Frankfurt am Main (Germany), Hannover (Germany), Milan
33. Viral Dynamics After Achieving Undetectable HDV RNA With Bulevirtide Monotherapy in Study MYR301
P. Lampertico, S. Aleman, M. Brunetto, P. Bogolomov, V. Chulanov, T. Stepanova, A. Lichtman, D. Manuilov, Z. Wang, M. Cornberg, S. Zeuzem, H. Wedemeyer
Milan, Stockholm (Sweden), Pisa, Moscow (Russian Federation), Foster City (USA), Hannover (Germany), Frankfurt (Germany)
34. Multidisciplinary Follow-up after Liver Transplantation: Diagnostic Yield and Impact on Cancer and Cardiovascular Outcomes
E.N. Lynch, A. Curto, M. Tanturli, R. G. Iamello, G. Lubian, E. Monaco, M. Vanni, T. Mello, T. Innocenti, G. Dragoni, S. Gitto, A. Galli
Florence
35. Early Protein C Pathway in Porto-Sinusoidal Vascular Disorder: A Potential Marker of Porto Sinusoidal Endothelial Dysfunction
K. Ferdinande, A. Zanetto, C. Bulato, E. Campello, S. Gavasso, E. Pinto, P. Simioni, M. Senzolo
Padua
36. Albumin as a predictor of long-term post-TIPS survival
C.B. Molteni, M. Lucà, G. Tosetti, C. Cicalini, M. Primignani, L. Argiento, S. Stella, P. Lampertico
Milan
37. TIPS for Refractory Ascites Ameliorates Trajectories, and Non-Acute Decompensation Status Favors Recompensation
K. Ferdinande, A. Zanetto, S. Groff, G. Barbiero, M. Battistel, C. Michele, A. Ferrarese, E. Pinto, G. Germani, M. Gambato, F. P. Russo, P. Burra, M. Senzolo
Padua
38. Predictors of hepatic encephalopathy after TIPS: a single-center retrospective analysis
C. Cicalini, M. Lucà, L. Argiento, G. Tosetti, C.B. Molteni, S. Stella, P. Lampertico
Milan
39. The high genetic variability of HDV sub-genotypes 1 can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity
L. Piermatteo, A. Magnapera, G. Torre, L. Carioti, S. D’Anna, L. Etogo, A. Bertoli, P. Paba, A. Olivero, E. Teti, A. Di Lorenzo, V. Malagnino, M. Iannetta, L. Baiocchi, S. Francioso, I. Lenci, U. Cillo, A. Vitale, G. Brancaccio, G.B. Gaeta, A. Ciancio, F. Ceccherini Silberstein, S. Grelli, L. Sarmati, M. Rizzetto, G.P. Caviglia, R. Salpini, V. Svicher
Rome, Turin, Padua, Naples
40. Global ROTEM (G-ROTEM) profile predicts major bleeding in patients with Acute-on-Chronic Liver Failure
E. Pinto, A. Zanetto, C. Bulato, E. Campello, K. Ferdinande, A. Ferrarese, M. Gambato, G. Germani, F.P. Russo, P. Burra, P. Simioni, M. Senzolo
Padua
41. Mapping Somatic Evolution in Steatotic Liver Disease through Integrated Tissue and Organoid Genomics
A. Cherubini, S. Mira, V. Moretti, H.E. Torgabehei, E. Casirati, L. Cerami, G. Periti, F. Malvestiti, S. Pelusi, D. Dondossola, D. Prati, L. Ronzoni, L. Valenti
Milan
42. Metabolic ferroptosis as targetable signature for the genetic subtype of MASLD
E. Paolini, M. Meroni, M. Longo, S. Badiali, M. Maggioni, A. L. Fracanzani, P. Dongiovanni
Milan
43. PreDEA Study, Prevention in Emergency Departments: the case of hepatic steatosis
V. D’Arpino, A. Fontana, A. Cirella, G. Sinatti, V. Caputo, S. J. Santini, C. Balsano
L’Aquila
44. Circulating reticulated platelets in hepatocellular carcinoma with and without liver cirrhosis
P. Guerra, S. Toffanin, C. Bulato, A. Bonato, S. Cagnin, C. Soldà, M. D. Rizzato, S. Lonardi, F. Bergamo, A. Zanetto, E. Pinto, M. Senzolo, S. Montagnese, P. Simioni, E. Campello, A. Martini
Padua
45. Longitudinal evaluation of neutrophil-to-lymphocyte ratio (NLR) as a prognostic biomarker in patients with hepatocellular carcinoma (HCC) treated with atezolizumab-bevacizumab
S. Ascari, F. Tovoli, E. Barchetti, A. Granito, B. Stefanini, F. Ravaioli, L. Braccischi, F. Piscaglia
Bologna
46. Intra-hepatic HDV activity can be sustained by HBsAg deriving from HBV-DNA integration and can modulate virological response to bulevirtide
S. D’Anna, I. Grossi, L. Piermatteo, A. Di Lorenzo, L. Carioti, G. Brancaccio, E. Teti, G. Torre, C. Tramontozzi, V. Malagnino, M. Iannetta, C. Pasquazzi, U. Cillo, A. Vitale, E. Gringeri, M.A. Magrofuoco, L. Baiocchi, S. Francioso, I. Lenci, A.M. Geretti, M. L. Abate, A. Olivero, G.B. Gaeta, L. Sarmati, M. Rizzetto, G. . Caviglia, V. Svicher, R. Salpini
Rome, Padua, Turin, Naples
47. Does Seronegative Autoimmune Hepatitis really exist?
F. Colapietro, C. D. Slooter, K. Zachou, D. di Zeo Sànchez, M. Robles-Dìaz, M. Garcìa-Cortés, S. Santopietro, V. Ronca, A. Gerussi, P. Invernizzi, R. J. Andrade, G.N. Dalekos, J. P. H. Drenth, Y. de Boer, A. Lleo
Pieve Emanuele (MI), Milan, Amsterdam (The Netherlands), Larissa (Greece), Málaga (Spain), Madrid (Spain), Monza
48. Distinct HBsAg isoform patterns reflect viral activity and disease stage in chronic HDV infection
I. Grossi, C. Tramontozzi, A. Magnapera, S. D’Anna, E. Dileo, A. Olivero, L. Piermatteo, G. Mengozzi, A. Ciancio, A. Loglio, M. Viganò, S. Fagiuoli, P. Colombatto, B. Coco, M.R. Brunetto, D. Angrisani, A.G. Lanza, C. Magni, A. Gori, V. Messina, M. Milella, A. Saracino, L. Marinaro, G. Cariti, V. Cossiga, F. Morisco, S. Cretella, G. Verucchi, E. Biliotti, G. D’Offizi, M. Feasi, E. Pontani, C. Coppola, R. Rapetti, M. Pirisi, A. Izzi, T. Santantonio, V. Di Marco, A. Marrone, N. Coppola, M. Rizzi, A.M. Cattelan, G.A. Niro, P. Toniutto, F.R. Ponziani, L.S. Belli, A. Federico, G. Bertino, M. Barone, M. Puoti, A. Civolani, M. Distefano, L. A. Surace, R. Cozzolongo, E.M. Cela, E. Teti, P. Lampertico, T. Stroffolini, R. Salpini, V. Svicher, M. Rizzetto, G. P. Caviglia
Rome, Turin, Bergamo, Milan, Pisa, Naples, Caserta, Bari, Bologna, Genoa, Gragnano (NA), Novara, Foggia, Palermo, Bergamo, Padua, San Giovanni Rotondo (FG), Udine, Catania, Bari, Cagliari, Siracusa, Lamezia Terme (CZ), Castellana Grotte (BA)
49. Hepatoprotective effects of Momordica charantia extracts in in vitro models of MASLD
D. Gabbia, I. Zanotto, A. Signor, S. Pettenuzzo, M. Colognesi, M. Roverso, S. Bogialli, S. De Martin
Padua
50. The impact of CFTR genotype on liver impairment in patients with cystic fibrosis
V. Cossiga, M. Capasso, E. Pellegrino, P. Iacotucci, S. Albano, L. Ferrillo, F. Mazzitelli, J. Somma, L. Ranieri, M. Guarino, V. Carnovale, F. Morisco
Naples
51. α-KG–Driven Immune Escape in Hypoxic MASLD- HCC: Amino Acid Metabolism at the Crossroads
B. Foglia, J. Nurcis, S. Sutti, G. Caviglia, C. Bocca, P. Carucci, S. Gaia, R. Romagnoli, E. Bugianesi, M. Parola, S. Cannito
Novara, Turin
52. Multidisciplinary clinic approach improves immunotherapy treatment outcomes in unresectable hepatocellular carcinoma: a multicentre retrospective study
A. Dalbeni, A. Auriemma, M. Vicardi, M. E. Bellucco, C. Mazzarelli, F. Villa, G. Dispinzieri, L.A. Natola, C. Soldà, S. Lonardi, L. Foltran, S. Torresan, S. Rota, T. Pressiani, L. Rimassa, D. Sacerdoti, M. Milella
Verona, Milan, Padua, Aviano (PN), Rozzano (MI), Pieve Emanuele (MI)
53. Statins in Cirrhosis and Its Complications: An Umbrella Review and Meta-Analysis of Systematic Reviews
A. Dalbeni, F. Cattazzo, M. Vicardi, L. A. Natola, V. Di Maria, D. Sacerdoti, F. Cinque, R. Lombardi
Verona, Milan
54. Changing Epidemiology and Clinical Presentation of Hepatic Cirrhosis: Data from the SORPRESA Cohort Study
T. Sarcina, M. Masarone, E. Errigo, P. Angeli, S. Incicco, F.R. Ponziani, L. Stella, G.G. Di Costanzo, D. Angrisani, A. Federico, M. Diallo, A. Pasta, G. Federici, E. Pompili, P. Torre, F. Morisco, L. Ranieri, N. Coppola, M. Stanzione, A. Aghemo, S. De Nicola, E. G. Giannini, V. Di Marco, M. Persico
Salerno, Palermo, Padua, Rome, Naples, Genoa, Bologna, Rozzano (MI)
55. The interplay of epigenetic and redox biomarkers in a mouse model of metabolic dysfunction-associated steatotic liver disease
M.R. Braghini, G. Andolina, F. Tiano, N. Panera, A. Pastore, C. De Stefanis, G. Di Giovamberardino, M. Pezzullo, A. Mosca, C. Balsano, A. Mangia, L. Miele, A. Alisi
Rome, L’Aquila, San Giovanni Rotondo (FG)
56. Impact of PNPLA3 p.I148M variant on qFibrosis-based liver fibrosis features in MASLD biopsies in the Milan Biobank cohort
G. Periti, K. Akbary, F. Malvestiti, M. Maggioni, S. Margarita, J. Rondena, L. Ronzoni, R. D’Ambrosio, D. Dondossola, A. Cherubini, S. Pelusi, D. Prati, D. Tai, L. Valenti
Milan, Singapore
57. Impact of pre-treatment serum albumin concentration on clinical outcomes in patients with cirrhosis and ascites receiving long-term albumin
E. Pompili, G. Zaccherini, S. Nardelli, S. Piano, C. Alessandria, S. Neri, F.G. Foschi, F. Levantesi, A. Airoldi, L. Simone, G. Svegliati-Baroni, S. Fagiuoli, F. Marra, R. Cozzolongo, G. Iannone, M. Biselli, O. Riggio, P. Angeli, M. Bernardi, M. Baldassarre, P. Caraceni
Bologna, Rome, Italy, Padua, Turin, Catania, Faenza (RA), Milan, Ferrara, Ancona, Bergamo, Florence, Castellana Grotte (BA)
58. SORPRESA-HCC: A Multicenter Study on the Changing Epidemiology of HCC in Cirrhosis
T. Sarcina, P. Torre, C. Celsa, P. Angeli, F.R. Ponziani, A. Liguori, G. G. Di Costanzo, D. Angrisani, A. Federico, M. Romeo, A. Pasta, G. Iannone, G. Zaccherini, M. Masarone, F. Morisco, V. Cossiga, N. Coppola, G. Stornaiolo, A. Aghemo, S. De Nicola, V. Di Marco, E. G. Giannini, M. Persico
Salerno
59. HCC incidence and risk stratification in patients with metabolic dysfunction-associated steatotic liver disease on long-term follow-up: a retrospective multicentre study
G.P. Caviglia, M. Guariglia, R. D’Ambrosio, R. Perbellini, P. Lampertico, F. Damone, G. Petralli, M. R. Brunetto, S. Pelusi, L. Valenti, A. Liguori, M. Pompili, L. Miele, A. Armandi, J.M. Schattenberg, F. Barutta, G. Gruden, E. Shahini, G. Giannelli, M. Dallio, A. Federico, G. Pennisi, S. Petta, M. Pirisi, F. Salomone, M. Sangineto, G. Serviddio, E. Bugianesi
Turin, Milan, Pisa, Rome, Mainz (Germany), Homburg (Germany), Castellana Grotte (BA), Naples, Palermo, Novara, Catania, Foggia
60. Unsupervised Machine Learning Reveals Distinct Quality-of-Life Clusters Across Autoimmune Liver Diseases
E. Merelli, D. Verda, A. Piazza, N. Uhlenbusch, R.J. A.L.M. Snijders, B. Löwe, A.W. Lohse, A. Braun, M. K. Janik, P. Milkiewicz, P. Kovats, M. Papp, B. Balogh, F. Bolis, L. Cristoferi, M. Carbone, P. Invernizzi, L. Aamann, H. Ytting, J. Madaleno, B. Canhão, E.T.T.L. Tjwa, J.P.H. Drenth, L. Grønbæk, H. Grønbæk, V. Ronca, K. Olsen, Y.H. Oo, A.J. van der Meer, B. Engel, A. Campos-Murguia, R. Taubert, Ö.M. Koc, M. Kramer, T.J. Gevers, C. Schramm, A. Gerussi
Monza, Genoa, Hamburg (Germany), Nijmegen (The Netherlands), Warsaw (Poland), Szczecin (Poland), Debrecen (Hungary), Milan, Copenhagen (Denmark), Coimbra (Portugal), Maastricht (The Netherlands), Aarhus (Denmark), Horsens (Denmark), Birmingham (UK), Rotterdam (The Netherlands), Hannover (Germany)
61. Unraveling GLUT3-Mediated Metabolic and Immune Modulation in Intrahepatic Cholangiocarcinoma through Multi-Omics Analysis
M. A. Polidoro, B. Franceschini, F. Milana, C. Soldani, L. Lambroia, R. Carriero, L. Evangelista, A. Aghemo, A. Aghemo, M. Donadon, M. Donadon, G. Torzilli, G. Torzilli, A. Lleo, A. Lleo
Rozzano (MI), Pieve Emanuele (MI), Novara
62. Gene expression dynamics of immune cells and its genetic determinants in primary sclerosing cholangitis
C. Caime, P. Demela, R. Asselta, P. Invernizzi, A. Gerussi, B. Soskic
Milan
63. Functional and molecular profiling of primary intrahepatic cholangiocarcinoma cell lines along its tissue histo-morphological spectrum
M. Franchitto, G. Carpino, D. Overi, S. Paradiso, T. De Luca, F. Belardinilli, G. Giannini, F. Razionale, F. Ardito, A. M. De Rose, F. Giuliante, E. Gaudio, D. Alvaro, V. Cardinale
Rome, Boston (USA)
64. Sustained and Clinically Meaningful Improvements in Moderate to Severe Pruritus Patients With Primary Biliary Cholangitis Treated With Seladelpar: Results From the ASSURE Study up to 30 Months
G.M. Hirschfield, A. E. Kremer, C. Levy, K.V. Kowdley, H. Elbeshbeshy, J. Heo, F. Frigerio, K.M. Kwon, J. Liu, C. Burk, D.B. Crittenden, M.J. Mayo
Toronto (Canada), Zürich (Switzerland), Miami (USA), Seattle (USA), St. Louis (USA), Busan (Republic of Korea), Milan, Foster City (USA), Dallas (USA)
65. Management of Primary Biliary Cholangitis in Italian Clinical Practice: Insights from a Retrospective Observational Real-World Analysis
V. Perrone, S. Mazzoni, F. Frigerio, L. Giannessi, L. Degli Esposti
Bologna, Milan
66. Disease Control as Evidenced by Longitudinal Transient Elastography Measurements in the ASSURE Study: 36 Months of Treatment With Seladelpar Is Associated With Stable or Improved Liver Stiffness in Patients With Primary Biliary Cholangitis
C.L. Bowlus, G.M. Hirschfield, A.M. Villamil, K.V. Kowdley, H. Elbeshbeshy, C. Corpechot, A.E. Kremer, P.J. Trivedi, Y. Kallis, S. H. Jeong, F. Frigerio, K.M. Kwon, V. de Ledinghen, X. Qi, D.B. Crittenden, C. Levy
Sacramento (USA), Toronto (Canada), Buenos Aires (Argentina), Seattle (USA) St. Louis (USA), Paris (France), Zürich (Switzerland), Birmingham (UK), London (UK), Seongnam (South Korea), Milan, Foster City (USA), Miami (USA)
67. BAG3 as a Fibrosis-Associated Biomarker in MASLD: Integration with PNPLA3 and TM6SF2 Genetic Risk
B.M. Motta, M. Festa, A. Rosati, A. Basile, T. Sarcina, M.C. Turco, M. Persico
Salerno, Baronissi (SA)
68. Seladelpar Is Associated With a Sustained Reduction in Cholestatic Markers and a Consistent Safety Profile in Patients With Primary Biliary Cholangitis Treated up to 48 Months in the Ongoing, Open-Label ASSURE Study
D. Pratt, E.J. Lawitz, C. L. Bowlus, F. Frigerio, K.M. Kwon, S. Proehl, X. Qi, R. P. Kustra, A.M. Villamil
Boston (USA), San Antonio (USA), Sacramento (USA), Milan, Foster City (USA), Buenos Aires (Argentina)
69. Impact of malnutrition and sarcopenia on survival in HCC treated with immune-based systemic therapy
L. Argiento, L. Canova, E. Alimenti, L. I. Belli, S. Rocchetto, M. Platì, F. Cicchetti, E. Xhepa, P. Biondetti, M. Bruccoleri, M. Iavarone, P. Lampertico
Milan
70. PSC-DM: development and validation of a clinical diagnostic model for distinguishing primary from secondary sclerosing cholangitis
M. Scaravaglio, R. V. Motta, L. Cristoferi, C. Maino, A. Marini, E. Nofit, E. Pesatori, C. Gallo, F. Bolis, D. D’Amato, A. Curto, F. Malinverno, A. Gerussi, R. Viganò, M. Viganò, S.J. Rossi, K. V. Kowdley, P. Invernizzi, A. Nardi, M. Carbone, E. L. Culver
Milan, Oxford (UK), Monza, Bergamo, Florence, Greenwood Village (USA), Seattle (USA), Rome
71. Steatosis speaks to the heart: early left ventricular global longitudinal strain impairment in metabolic dysfunction-associated steatotic liver disease
C. Giglio, E. Lodi, B. Lei, A. Colecchia, L. Carulli
Modena
72. HCV screening and linkage to care in the 1969-1989 birth-cohort population: the Bergamo experience
L. Dell’Oro, A. Loglio, L. Rota, L. Ongis, D. Isabella, L. Pasulo, G. Bombardieri, M. G. E. Arosio, S. Fagiuoli
Milan, Bergamo
73. Exploring the hepatoprotective potential of psilocybin microdosing in steatohepatitis: in vitro and in vivo studies
A. Signor, M. Colognesi, D. Gabbia, A. Mattarei, S. Comai, G. Pasut, F. Folli, P. L. Manfredi
Padua, Milan, Kerhonkson (USA)
74. Multidisciplinary management of adult patients with Fontan Associated Liver Disease
G. Tomaiuolo, M. Saracco, S. Strona, C. Manuli, R. Lasco, M. H. Falzone, R. Gastaldi, E. Gribaudo, G. Annoni, F. Ferroni, C. P. Napoleone, M. Boffini, M. Rinaldi, R. Romagnoli, S. Martini
Turin
75. Spatial Proteomics Uncovers Region-Specific Proteomic Signatures in Autoimmune Liver Diseases
E. Merelli, V. Denti, G. Capitoli, C. Caime, G. Cazzaniga, M. Cadamuro, F. Malinverno, L. Cristoferi, A. Smith, F. Pagni, P. Invernizzi, F. Magni, I. Piga, V. L’Imperio, M. Carbone, A. Gerussi
Monza, Milan
76. Prospective evaluation of the effects of GLP1 receptor agonists and SGLT2 inhibitors in MASLD patients with type 2 diabetes
A. Mega, C. Turri, F. Vittadello, L. Marzi, R. Sacco, C. Stasi, M. Zöschg, E. Lorefice, A. Floreani
Bolzano, Padua, Foggia, Rome, Empoli (FI), Padua, Negrar (VE)
77. Predictors of clinical course in patients surviving an acute decompensation of cirrhosis
C. Gambino, A. Accetta, E. Pompili, R. Filomia, C. Passalacqua, G. Iannone, C. Pitrone, G. Fusco, C. Asero, G. La Manna, G. Zaccherini, I. Cacciola, G. Squadrito, P. Caraceni, P. Angeli, S. Piano
Padua, Bologna, Messina
78. ELF score and its components predict clinical outcomes after TIPS
L. Lani, M. Hintersteininger, T. Müllner-Bucsics, S. Riegler, G. Kramer, C. Sebesta, P. Thöne, B. Simbrunner, L. Reider, M. Weiss-Tessbach, R. Marculescu, M. Schoder, M. Trauner, M. Mandorfer, T. Reiberger, L. Hartl
Bologna, Vienna (Austria)
79. Quality of life during Transition after Liver Transplantation
F. Leonardi, A. Merisio, P. Stroppa, L. Pasulo, M. Triolo, F. Ideo, V. Casotti, D. Pinelli, M. S. Spada, L. D’Antiga, S. Fagiuoli
Bergamo
80. HBsAg trajectories might predict virological outcomes in patients with chronic hepatitis B infection
S. Battistella, A. Roca, A. Pocurull, Z. Marino, S. Rodriguez-Tajes, X. Forns, S. Lens
Padua, Barcelona (Spain)
MARCH 20th, 2026
1. Two-tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: A multicenter cross- sectional study
A. Mantovani, R. Lombardi, A. Dalbeni, R. Morandin, M. G. Lando, V. Fiorio, N. Rolli, M. Forti, D. Messetti, M. Zoncapè, I. Milani, M. E. Parrotta, D. Capoccia, V. Guglielmi, F. Leonetti, P. Sbraccia, A.L. Fracanzani, G. Targher
Verona, Milan, Latina, Rome
2. GAAD score as a diagnostic and prognostic marker from cirrhosis to hepatocellular carcinoma
S. Cagnin, A. Aita, A. Biasiolo, G. Tretti, S. Quarta, A. Stefani, M. Ruvoletto, P. Guerra, R. Donghia, G. Giannelli, P. Pontisso, M. Montagnana, A. Martini
Padua, Castellana Grotte (BA)
3. The evolving landscape of TIPS. From traditional indications to everyday clinical practice
Y. Capraro, L. Lamfu, R. Argirò, D. Morosetti, I. Lenci, M. Milana, L. Baiocchi
Rome
4. Blood Metabolomic Signature for Diagnosing Cirrhosis and Predicting Prognosis in Patients with Primary Sclerosing Cholangitis
E. Catanzaro, A. Lapitz, P. Milkiewicz, M. Elgozair, F. Ahmed, J.R. Hov, T. Folseraas, M. Carbone, R.I.R. Macias, C. Schramm, C. Alonso, M. Milkiewicz, L. Izquierdo-Sánchez, A. La Casta, R. Jimenez-Aguero, M. J. Perugorria, L. Cristoferi, M. Arrese, J. Chahuan, J. Bustamante, M. Dill, S. Rossi, M. Walmsley, L. Bujanda, L. Roberts, T.H. Karlsen, L. Fabris, N. Cazzagon, P.M. Rodrigues, J. M. Banales
Padua, San Sebastian (Spain), Warsaw (Poland), Rochester (USA), Oslo (Norway), Milan, Salamanca (Spain), Hamburg (Germany), Derio (Spain), Szczecin (Poland), Monza, Santiago (Chile), Barakaldo (Spain), Heidelberg (Germany), Denver (USA), Manchester (UK)
5. Long-term outcomes of patients with Porto-Sinusoidal Vascular Disorder, with or without portal hypertension features
E. Farina, A. Loglio, G. Colloredo, A. Sonzogni, F. Cerini, C. Severgnini, L. Licini, P. Tebaldi, P. Marra, A. Gianatti, S. Fagiuoli, M. Viganò
Bergamo, Milan, Ponte San Pietro (BG), Seriate (BG), Milan
6. Real-life evaluation of the FIB-4 two-step fibrosis screening algorithm in MASLD: measurement of waist circumference might make the difference
R. Lombardi, F. Cinque, A. Cespiati, F. Alletto, D. Smith, G. Oberti, E. Fatta, E. Pulixi, G. Maffi, A. Mantovani, A. Dalbeni, A. L. Fracanzani
Milan, Verona
7. Lysosomal acid lipase (LAL) activity is inversely associated with histological progression of metabolic dysfunction-associated steatotic liver disease (MASLD): a single-centre prospective study
R. Lombardi, F. Cinque, A. Cespiati, C. Bertelli, G. Pisano, G. Oberti, J. Currà, E. Calzavara, F. Alletto, C. Garavaglia, G. Cincotto, M. Gomaraschi, A. L. Fracanzani
Milan
8. Long-term albumin treatment improves outcomes in patients with cirrhosis and ascites
V. Santori, M. Tonon, N. Torp, E. Pompili, L. Balcar, C. Lobel, R. Gagliardi, J. Embacher, M. Israelsen, A. Accetta, S. Johansen, L. Hafner, M. Trauner, M. Mandorfer, T. Reiberger, A. Krag, P. Caraceni, P. Angeli, S. Piano, G. Semmler
Padua, Odense (Denmark), Bologna, Vienna (Austria)
9. Reprogramming of tumour-associated macrophages in liver affected by colorectal cancer metastases
C. Cives-Losada, C. Soldani, B. Franceschini, M.A. Polidoro, A. Gazzillo, A. Cammarota, F. Milana, F. Clemente, A. Anselmo, L. Di Tommaso, G. Torzilli, M. Donadon, A. Lleo
Novara, Rozzano (MI), Milan, Pieve Emanuele (MI)
10. Lower resilience and perceived social support in pbc patients: fatigue as a major determinant of psychological adaptation
C. Sgamato, R. Clavo, L. Pisciotta, P. De Crescenzo, L. Romano, A. Torriero, P. Coccoli, G. Nardone, A. Rocco
Naples
11. LiverCARD: opportunistic Cardiovascular Risk assessment in MASLD using a multimodal AI pipeline
A. Cirella, P. Bruno, A. Quarta, E. De Rose, V. Caputo, S.J. Santini, G. Greco, P. Palumbo, S. Germano, M. Vinci, F. Calimeri, E. Di Cesare, A. Guzzo, C. Balsano
Rende (CS), L’Aquila, Rome
12. Portal Hypertension: multiple treatment to reach the goal
S.S. Sciarrone, M. Arena, G. Iabichino, M. Di Leo, L. Fini, A. Losco, S. Zatelli, D. Viganò, G. Tagliamonte, A. Murru, L. De Luca
Milan
13. MASLD and Mental Health: association of the liver disease with anxiety, depression and binge eating
S. De Nicola, A. Bertazzoni, A. Catena, N. Pugliese, C. Masetti, V. Ronca, B. Mazzuccato, A. Lleo, M. Cucchi, A. Aghemo
Rozzano (MI), Pieve Emanuele (MI)
14. PSVD: specific histological features and risk of PVT
M. Lucà, L. Valenti, L. Argiento, C. Cafasso, C. Cicalini, C. B. Molteni, G. Tosetti, M. Primignani, S. Stella, M. Maggioni, P. Lampertico
Milan
15. Obesity drives mild cognitive impairment in metabolic-associated steatotic liver disease
C. Sgamato, R. Clavo, L. Pisciotta, C. Miele, A. Torriero, P. Coccoli, G. Nardone, A. Rocco
Naples
16. Diagnostic performance of available biomarkers for Hepatocellular Carcinoma: a comprehensive meta regression analysis
A. Dalbeni, M. Vicardi, L. A. Natola, F. Cattazzo, M. Bevilacqua, L. Dalle Carbonare, D. Sacerdoti
Verona
17. Liver Transplantation for Primary Sclerosing Cholangitis: A 35-Year Single-Center Experience at ASST GOM Niguarda
D. D’Amato, C. Mazzarelli, A. Curto, A. Airoldi, F. Aprile, C. Becchetti, M. Cucco, G. Dispinzieri, G. Perricone, M. Vangeli, F. Bolis, A. Bonfichi, M. Clemente, L. S. Belli, A. Lauterio, R. Viganò, M. Carbone
Milan, Florence
18. Risk factors in Intrahepatic Cholangiocarcinoma a Single-Center Cohort Analysis
D. Costantino, M. De Giorgio, P. Rossi, C. Severgnini, S. Fagiuoli
Bergamo, Milan
19. A Global Delphi Consensus Involving Patients, Industry, Clinicians, and Regulators on Surrogate Endpoints and Real-World Evidence in Primary Biliary Cholangitis: an EASL-AASLD Framework for Therapeutic Development
M. Scaravaglio, A. Martins, C.L. Bowlus, C.A. Couto, C. Corpechot, B.E. Hansen, G.M. Hirschfield, D.E.J. Jones, M.J. Mayo, A. Villamil, J. Willemse, C. Levy, M. Carbone, A. Lleo
Monza, Miami (USA), Sacramento (USA), Belo Horizonte (Brazil), Paris (France), Rotterdam (The Netherlands), Toronto (Canada), Newcastle (UK), Dallas (USA), Buenos Aires (Argentina), Hoogland (The Netherlands), Milan
20. Glucagon-Like Peptide-1 Receptor Agonists and Hepatocellular Carcinoma prevention: a meta -analysis and clinical decision framework
M. Vicardi, A. Dalbeni, L. A. Natola, F. Cattazzo, A. Auriemma, R. Lombardi, F. Cinque, A. Mantovani, L. Dalle Carbonare, D. Sacerdoti
Verona, Milan
21. Efficacy and Safety of Mycophenolate Mofetil as First and Second line Therapy in Autoimmune Hepatitis: A Retrospective Single-center Analysis according to Azathioprine Exposure and Response
M. Clemente, D. D’Amato, C. Becchetti, F. Berardi, L.S. Belli, M. Carbone, R. Viganò
Milan
22. FiOCA Study: Comparative Transplant-Free Survival in Primary Biliary Cholangitis Patients Receiving Obeticholic Acid or Fibrates.
V. Ronca, A. De Vincentis, A. Tanaka, C. Corpechot, P. Trivedi, F. Terracciani, L. Cristoferi, G. Cancado, M. Scaravaglio, N. Cazzagon, N. Abbas, K. Olsen, S. Rodriguez-Tajes, A. Martins, F. Colapietro, M.C. Londoño, N. Gatselis, V. Lygoura, E. Lytvyak, A. Montano-Loza, A. Gerussi, E. Culver, G. Dalekos, D. D’Amato, A. van der Meer, F. Nevens, E. Zigmond, V. Calvaruso, L. Sierra, R. Barba, A. Bonder, A. Villamil, X. Verhelst, C. Levy, H. Ytting, R. Viganò, M. Viganò, A. Lleo, P. Invernizzi, U. Vespasiani-Gentilucci, G. Hirschfield, B. Hansen, M. Carbone
Pieve Emanuele (MI), Rozzano (MI), Rome, Tokyo (Japan), Paris (France), Birmingham (UK), Belo Horizonte (Brazil), Padua, Miami (USA), Larissa (Greece), Alberta (Canada), Oxford (UK), Rotterdam (The Netherlands), Leuven (Belgium), Tel Aviv (Israel), Palermo, Boston (USA), Buenos Aires (Argentina), Ghent (Belgium), Copenhagen (Denmark), Milan, Bergamo, Toronto (Canada), Monza
23. Impact of Liver Histology and MASLD-Associated Genetic Variants on Insufficient Weight Loss After Bariatric Surgery
F. Cinque, S. Badiali, M. Meroni, M. Longo, E. Paolini, E. Galfrascoli, G. Oberti, G. Pisano, E. Calzavara, A. Cespiati, L. Boni, P. Dongiovanni, R. Lombardi, A. L. Fracanzani
Milan
24. Clinical Presentation and Determinants of Disease Progression in Cirrhosis: data from the SORPRESA Study Cohort
V. Calvaruso, G. Di Maria, P. Angeli, S. Incicco, F.R. Ponziani, A. Liguori, G.G. Di Costanzo, D. Angrisani, A. Federico, M. Romeo, A. Pasta, P. Caraceni, S. Bighini, M. Masarone, F. Morisco, M. Guarino, N. Coppola, G. Stornaiuolo, A. Aghemo, S. De Nicola, C. Cammà, M. Persico, E.G. Giannini, V. Di Marco
Palermo, Padua, Rome, Naples, Genoa, Bologna, Salerno, Rozzano (MI)
25. Comparison between radiologic pre-liver transplant assessment of the presence and size of HCC and the histological findings obtained in the explanted liver
E. Garlatti Costa, D. Bitetto, E. Fumolo, E. Fornasiere, D. Lorenzin, A. Tulisso, U. Baccarani, P. Toniutto
Udine
26. Real-world experience with Elafibranor in patients with Primary Biliary Cholangitis previously treated with Obeticholic Acid: an Italian Multicenter Observational Study
M. Viganò, D. Montecalvo, S. Labanca, F. Ponziani, E. N. Lynch, M. Distefano, F. Terracciani, M. Cannavò, V. Ronca, L. Cristoferi, A. Gerussi, C. De Benedittis, V. Pace Palitti, L. Napoli, T. Zolfino, G. Alagna, V. Calvaruso, A. Moretti, G. Rizzo, M. Marzioni, N. Cazzagon, E. Lorefice, D. Roccarina, R. Cozzolongo, L. Scribano, G. Vitale, B. Coco, A. Pellicelli, F. Cerini, A. Castellaneta, C. Fabbri, A. Andrealli, A. Garribba, L. Fabris, E. Pesatori, A. Loglio, A. Grossi, S. Cariati, L. Stella, M. Russello, A. Lleo, C. Rigamonti, A. Galli, U. Vespasiani Gentilucci, D. Alvaro, E. Nofit, S. Fagiuoli, M. Carbone, P. Invernizzi, E. G. Giannini
Rome, Genoa, Florence, Siracusa, Catania, Milan, Monza, Novara, Pescara, Faenza (RA), Cagliari, Sassari, Palermo, Chieti, Ancona, Padua, Empoli (FI), Castellana Grotte (BA), Bologna, Pisa, Bari, Como, Ravenna
27. Minimally invasive hybrid Transjugular and Percutaneous PortoHepatic Pressure Gradient measurement (hTP-PHPG): safety and diagnostic value in patients with undefined or mixed-etiology portal hypertension
D. Saltini, M. Bianchini, A. S. Velasco Mayorga, T. Guasconi, G. Lo Cascio, A. Piscopo, N. Giglio, F. Scianò, F. Milosa, R. M. Critelli, A. Colecchia, F. Schepis
Modena
28. Quantified EEG improves prediction of recurrent overt hepatic encephalopathy after elective TIPS: development and internal validation of a multivariable model
D. Saltini, L. Zarantonello, A. Zanetto, T. Guasconi, C. Caporali, A. Piscopo, A. S. Velasco Mayorga, M. Scoppettuolo, F. Milosa, R. M. Critelli, N. Giglio, F. Scianò, F. Casari, F. Ascari, M. Bianchini, A. Colecchia, M. Gaggini, F. Vizzutti, S. Montagnese, F. Schepis
Modena, Padua, Pisa, Florence
29. Socioeconomic Deprivation and Clinical Characteristics of Patients with Newly-Diagnosed Cirrhosis in Italy: Evidence from the SORPRESA Cohort
A. Pasta, S. Cariati, A. Lombardo, P. Angeli, S. Incicco, F.R. Ponziani, L. Stella, G.G. Di Costanzo, D. Angrisani, A. Federico, M. Dallio, G. Pilara, G. Zaccherini, M. Masarone, F. Morisco, M. Capasso, N. Coppola, M. Stanzione, A. Aghemo, S. De Nicola, M. Persico, V. Di Marco, E.G. Giannini
Genoa, Palermo, Padua, Rome, Naples, Bologna, Salerno, Rozzano (MI)
30. Integrated tissue and liquid biopsy analysis of KDM2A expression in hepatocellular carcinoma
T. Caruso, S. Cesario, I. De Giorgi, F. Salani, F. Pratesi, M.C. Scavuzzo, V. Genovesi, C. Vivaldi, P. Faviana, F. Bartoli, P. Colombatto, F. Di Lella, M.R. Brunetto, G. Cavallini, G. Masi, V. Carloni, L. Gragnani
Pisa, Florence
31. A serology-based algorithm combining total anti-HDV, anti-HDV IgM, and ALT to predict high levels of circulating HDV-RNA
G. Caviglia, E. Dileo, G. Gioiello, S. Limoncelli, A. Olivero, G. Mengozzi, A. Ciancio, A. Loglio, M. Viganò, S. Fagiuoli, P. Colombatto, B. Coco, M.R. Brunetto, D. Angrisani, A. Galeota Lanza, C. Magni, A. Gori, V. Messina, M. Milella, A. Saracino, L. Marinaro, G. Cariti, V. Cossiga, F. Morisco, S. Cretella, G. Verucchi, E. Biliotti, G. D’Offizi, M. Feasi, E. Pontali, C. Coppola, R. Rapetti, M. Pirisi, A. Izzi, T. Santantonio, V. Di Marco, A. Marrone, N. Coppola, M. Rizzi, A.M. Cattelan, G. A. Niro, P. Toniutto, F. R. Ponziani, L.S. Belli, A. Federico, G. Bertino, M. Barone, M. Puoti, A. Civolani, M. Distefano, L.A. Surace, R. Cozzolongo, E. M. Cela, E. Teti, P. Lampertico, T. Stroffolini, M. Rizzetto
Turin, Bergamo, Milan, Pisa, Naples, Caserta, Bari, Bologna, Rome, Genoa, Gragnano (NA), Novara, Foggia, Palermo, Padua, San Giovanni Rotondo (FG), Udine, Catania, Cagliari, Siracusa, Lamezia Terme (CZ), Castellana Grotte (BA)
32. Development of new criteria for assessing response to plasma volume expansion at 24 hours in patients with cirrhosis and Acute Kidney Injury
S. Incicco, R. Gagliardi, M. Tonon, V. Calvino, N. Zeni, C. G. Gambino, P. Angeli, S. Piano
Padua
33. Validation of the RETREAT Score for Predicting Hepatocellular Carcinoma Recurrence After Liver Transplantation: Evidence from an Italian Multicenter Cohort
L.A. Natola, V. Paon, M. Vicardi, A. Filice, A. Dalbeni, F. Cattazzo, L. Canova, E. Alimenti, G.M.F. Marini, A. Borin, D. Dondossola, A. Carraro, M. Iavarone, D. Sacerdoti
Verona, Milan
34. PNPLA3 polymorphisms and risk of hepatic and extrahepatic outcomes in MASLD: a systematic review and meta-analysis
C. Celsa, G. Pennisi, A. Tulone, G. Ciancimino, M. Vaccaro, F. Pecorella, G. Di Maria, M. Enea, C. Cammà, S. Petta
Palermo
35. Alcoholic acute-on-chronic liver failure vs alcoholic cirrhosis: clinical outcomes after liver transplantation. A single center experience
C. Sicuro, N. De Maria, R. Cuoghi Costantini, M. Montanari, M. Scoppettuolo, A. Colecchia, F. Di Benedetto, P. Magistri
Modena
36. The Italian PBC Registry: Insights from a Nationwide Cohort Study
E. Nofit, L. Cristoferi, A. Gerussi, D. D’Amato, M.M. G. Festa, E. Bonaiuto, V. Di Marco, F. Azzaroli, E. Dajti, F. Colapietro, P. Lampertico, E. Degasperi, S. Fagiuoli, M. Viganò, A. Castellaneta, A. De Feudis, E. G. Giannini, S. Labanca, F. Terracciani, G. Raimondo, C. Saitta, M. Russello, M. Cannavò, E. Vanni, A. Risso, F. Morisco, V. Cossiga, C. Rigamonti, G. F. Manfredi, G. Missale, A. Orlandini, F. Losito, R. Cozzolongo, E. N. Lynch, A. Galli, A. Curto, L. Maroni, M. Brunetto, B. Coco, F. Cerini, F. Pavan, F. Bellanti, S. Quiete, L. Napoli, F. Foschi, A. Mega, M. Zoeschg, A. Granito, F. Piscaglia, G. Vitale, M. C. Morelli, V. Pace Palitti, M. Persico, T. Sarcina, L. A. Surace, E. Falbo, R. Viganò, F. D’Amico, D. Alvaro, S. Nardelli, D. Montecalvo, G. Nardone, A. Rocco, G. Vettori, . Moser, C. Ricci, P. Poisa, F. Bronte, A. Affronti, A. Federico, F. Di Nardo, C. Cusumano, C. Agnolon, G. Alagna, I. Cavalli, A. Gobbi, M. C. Bragazzi, R. Venere, A. Mangia, V. Piazzolla, F. Ponziani, F. Fianchi, P. Andreone, F. Gabrielli, T. Zolfino, C. Scudu, G. Niro, R. Cotugno, L. Fabris, A. Lasagni, S. L. Crocè, F. Masutti, L. Chessa, F. Pes, P. Lecis, A. Meneghetti, L. Muratori, M. L. Panico, L. Baiocchi, P. Carnì, S. Segato, E. Grassi, F. Capelli, L. Pitotti, L. Abenavoli, G. G. M. Scarlata, A. Baragiotta, F. Marra, F. Biagi, N. Dal Bo’, S. Schianchi, M. Beltrami, R. Chiavaroli, M. Graffeo, N. Cazzagon, V. Calvaruso, A. Lleo De Nalda, U. Vespasiani Gentilucci, M. Marzioni, M. Carbone, P. Invernizzi
Monza, Padua, Palermo, Bologna, Rozzano (MI), Milan, Bergamo, Bari, Genoa, Roma, Messina, Catania, Turin, Naples, Novara, Parma, Castellana Grotte (BA), Florence, Ancona, Pisa, Foggia, Faenza (RA), Bolzano, Pescara, Salerno, Lamezia Terme (CZ), Trento, Brescia, Verona, Sassari, Cremona, Latina, San Giovanni Rotondo (FG), Modena, Cagliari, Trieste, Monserrato (CA), Bassano del Grappa (VI), Varese, Legnano (MI), Catanzaro, Pordenone, Treviso, Reggio Emilia
37. SAMOTHRACE: AI-Supported Telemonitoring to Detect Early Decompensation in Cirrhosis Awaiting Liver Transplantation
C.M. Giacchetto, G. Enea, V. Lo re, B. Magro, G. Pietrosi, D. Terzo, D. Lo bello, D. Bellavia, N. Rizzitello, M. Larafa, E. Randazzo, M. Pinzani, S. Gruttadauria, A. Galante, G. Martucci
Palermo
38. MASLD-related hepatocellular carcinoma in cirrhotic and non-cirrhotic patients: a realworld analysis from the ITA.Li.Ca. cohort
L. Ragozzino, A. Mastro, T. V. Li Cavoli, A. Toscano, T. Zurli, V. Adotti, F. Marra
Florence, Messina
39. Assessment of Hepatocellular Carcinoma Risk in Non-Cirrhotic Individuals with HCV Infection Following SVR Achievement with DAA Therapy: A Single-Center Retrospective Longitudinal Observational Analysis
A. Salvaderi, L. Maiocchi, M. Gerola, P. Angelini, S. Lerta, G.P. Peroò, G. Sangaletti, S. Corallo, A. Lasagna, B. Caccia, G. Albi, R. Bruno, V. Zuccaro
Pavia
40. Impact of Incidental Computed Tomographic Ischemic Areas After Liver Transplantation: Associations with Donor Type, Perfusion Strategy, and Clinical Outcomes
D. Pagano, G. Mamone, F. di Francesco, C. Celsa, A. Galante, M. C. Giacchetto, S. Li Petri, C. Camma’, N. Di Lorenzo, S. Gruttadauria
Palermo
41. Enhancing Guideline-Concordant Decision Support in Hepatology: A Retrieval-Augmented Generation Framework Evaluated Across Five Major Hepatology Clinical Domains
M. Giuffrè, S. Kresevic, F. Orbosuè, M. Gulotta, L. Fusaro, A. Distefano, A. Accardo, M. Ajcevic, L.S. Crocè
Trieste
42. Endoscopic ultrasound Guided Portal Pressure Gradient: Prognostic Utility and Concordance With the Hepatic Venous Pressure Gradient
L. Giuli, A. Larghi, G. Rizzatti, M. Pallozzi, C. Cavallo, G. Venturini, F. R. Ponziani, B.E. Annicchiarico, G. Tripodi, A. Contegiacomo, R. Iezzi, R. Talerico, A. Gasbarrini, F. Santopaolo
Rome
43. A Multi-Agent Large Language Model Framework that Simulates a Multidisciplinary Tumor Board for Hepatocellular Carcinoma Management
M. Giuffrè, F. Ma, A. Visintin, L. Fusaro, M. Gulotta, M. Sartori, F. Masutti, L. S. Crocè
New Haven (USA), Trieste
44. Platelets mirror disease severity in Metabolic dysfunction-Associated Steatotic Liver Disease
M. Zoncapè, M. Castelli, A. Meneguzzi, A. Mantovani, D. Sacerdoti, P. Minuz, A. Dalbeni
Padua, Verona
45. A machine learning–powered tool o characterize cholangiocarcinoma prognosis
G. De Sario, L. Manganaro, G. Carpino, F. Biancaniello, M.C. Bragazzi, M. Franchitto, M. Franchitto, S. Paradiso, T. De Luca, D. Overi, A. Ducato, C. Ferrari, G. Tortorelli, F. Ardito, A.M. De Rose, F. Razionale, F. Giuliante, G.L. Grazi, E. Gaudio, D. Alvaro, V. Cardinale
Rome, Turin, Florence, Boston (USA)
46. Diagnostic yield of a targeted Next Generation Sequencing (NGS) cholestasis-gene panel in adult with unexplained cholestatic liver disease: a multicenter Italian cohort study
L. Cristoferi, D. D’Amato, F. Terracciani, L. Ronzoni, P. Colombatto, A. Curto, S. Labanca, C. De Benedittis, S. Nardelli, B. Coco, E. Mensi, A. Gerussi, F. Malinverno, E. N. Lynch, D. Montecalvo, L. Casella, M. Distefano, G. Alagna, M. Viganò, A. Cereda, F. Bertola, A. Caserta, V. Calvaruso, C. Rigamonti, D. Alvaro, M.R. Brunetto, A. Galli, L. Valenti, E. G. Giannini, M. Carbone, P. Invernizzi, U. Vespasiani Gentilucci
Monza, Rome, Milan, Pisa, Florence, Genoa, Novara, Siracusa, Sassari, Bergamo, Palermo
47. Early detection of minimal hepatic encephalopathy using wearable sensors
C. Asero, M. S. Franzè, C. Ligresti, A. Battaglia, C. Saitta, R. Filomia, G. Caccamo, C. Pitrone, D. Milone, C. De Marchis, I. Cacciola
Messina, Palermo
48. Non-invasive tests for liver fibrosis are inhaccurate to screen for advanced fibrosis in general adult population
M. Tonon, V. Calvino, R. Gagliardi, S. Incicco, N. Zeni, V. Santori, A. Accetta, G. Antonacci, A. Martini, M. Crescenzi, A. Zanetti, P. Angeli, S. Piano
Padua
49. From Cure to Complexity: Post-SVR Liver and Metabolic Trajectories in Diabetic Patients
C. Asero, M. S. Franzè, T. Maltese, A. La Spada, D. Lombardo, C. Grisanti, R. Filomia, G. Caccamo, C. Pitrone, C. Saitta, T. Pollicino, I. Cacciola
Messina
50. Metabolome analysis revealed red flag signatures for the identification of MASLD risk across patients with dysmetabolic traits
M. Longo, M. Meroni, E. Paolini, G. Paolella, R. Lombardi, V. Flagiello, J. Avagliano, C. Garavaglia, E. Polledri, R. Mercandate, P. Gallo, F. Terracciani, S. Fustinoni, C. Agostoni, M. Gomaraschi, U. Vespasiani-Gentilucci, A. Fracanzani, P. Dongiovanni
Milan, Rome, Naples, Salerno
51. Stereotactic Body Radiotherapy for the treatment of HCC: a single center experience
C. Mazzarelli, A. Maver, L. S. Belli, M. Palazzi, F. Bracco, A. Casbarra, F. Tosi, K. Bencardino, I. Vicentin, C. Sgrazzutti, A. Lauterio, D. Sibio
Milan
52. Cabozantinib for Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Multicenter Clinical Experience
C. Mazzarelli, F. Tosi, G. Mauri, M. Sagasta, C. Di Benedetto, E. Alimenti, M. A. Iavarone, D. Costantino, M. De Giorgio, L. S. Belli
Milan, Bergamo
53. Prevalence and Determinants of Elevated FIB-4 in Adults from Primary Care
M. Montori, D. Balducci, G. M. Corradini, M. Ricci, E. Fiorini, P. Core, P. Lodolini, A. Marracino, M. Luzi, M. D. Giulioni, G. Sampaolo, M. Zucchi, A. Pini, R. Deliberato, E. Zucchi, A. Di Giovannangelo, A. Lucarelli, G. Svegliati Baroni
Ancona
54. Comparative analysis of albumin microheterogeneity and metabolic signatures in portal, hepatic, and peripheral circulation: prognostic implications in patients with cirrhosis undergoing TIPS
M. Baldassarre, S. Di Cola, S. Nardelli, G. Cusi, E. Pompili, G. Tedesco, M. Naldi, A. Perrone, W. Mensah, M. Bartolini, P. Caraceni, M. Merli
Bologna, Rome
55. The Role of Atezolizumab and Bevacizumab in Unresecable Hepatocellular Carcinoma: from neoplastic portal invasion to extrahepatic metastasis a prospective study from ARTE dataset
F. Cattazzo, M. Bevilacqua, M. Vicardi, V. Di Maria, M. Iavarone, G. Cabibbo, F. Marra, C. Vivaldi, F.R. Ponzani, A. Palloni, S. Lonardi, L. Lani, P. Federico, G. Svegliati-Baroni, T. Pressani, L. Ielasi, C. Mazzarelli, S. De Lorenzo, R. Sacco, M. Bruccoleri, C. Celsa, C. Campani, G. Masi, L. Stella, P. Toniutto, R. Villani, M. Dibetto Dimondini, F. Tovoli, D. Sacerdoti, A. Auriemma, A. Dalbeni
Verona, Milan, Palermo, Firenze, Pisa, Roma, Bologna, Padova, Napoli, Ancona, Rozzano (MI), Faenza (RA), Foggia, Udine
56. Long-term cohort analysis of HBV Basic Core Promoter, Pre-Core, and Core Region heterogeneity
D. Cavallone, G. Ricco, P. Colombatto, B. Coco, B. Vianello, A. Calì, F. Bonino, M. R. Brunetto
Pisa
57. HCV testing and linkage-to-care practices in a tertiary hospital in Southern Italy underscore the need for routine screening and treatment programs
P. Torre, E. Serretiello, G. Di Siervi, E. Vaccaro, T. Sarcina, M. Festa, V. Folliero, G. Boccia, M. Masarone, G.L. Franci, M. Persico
Salerno, Baronissi (SA)
58. Hemodynamic alterations of porto-sinusoidal vascular disease (PSVD) with portal hypertension evaluated by Doppler-sonography
M. Bevilacqua, F. Cattazzo, F. Smaldone, M. Ferrari, B. Vescovi, S. Marin, S. Grisenti, S. Romeo, A. Filice, L. Natola, V. Paon, D. Ieluzzi, A. Dalbeni, A. Mantovani, D. Sacerdoti
Verona
59. The burden of cirrhosis admissions with extrahepatic organ failures in Italy
R. Gagliardi, A. Barone, S. Incicco, M. Tonon, C.G. Gambino, V. Calvino, A. Accetta, V. Santori, N. Zeni, P. Angeli, S. Piano
Padua
60. Non-invasively estimated risk of clinically significant portal hypertension is a predictor of hepatic decompensation in compensated advanced chronic liver disease of different etiologies
C. Rigamonti, C. Tacchelli, P. Lorenzon, G.F. Manfredi, C. De Benedittis, S. Casella, M.E. Burlone, M. Pirisi
Novara
61. ESC and CARDIOSOR scores as easy tools to stratify cardiovascular risk in patients with HCC treated with atezolizumab/bevacizumab
M. Dibetto Rimondini, B. Stefanini, L. Rimassa, M. Iavarone, G. Cabibbo, F. Marra, C. Vivaldi, A. Dalbeni, F. R. Ponziani, A. Palloni, S. Lonardi, L. Lani, P. Federico, G. Svegliati-Baroni, T. Pressiani, L. Ielasi, C. Mazzarelli, S. De Lorenzo, R. Sacco, M. Bruccoleri, C. Celsa, A. Auriemma, L. Stella, P. Toniutto, R. Villani, A. Granito, F. Tovoli, F. Piscaglia
Bologna, Pieve Emanuele (MI), Rozzano (MI), Milan, Palermo, Florence, Pisa, Verona, Rome, Padoua, Naples, Ancona, Faenza (RA), Foggia, London (UK), Udine
62. Multidimensional frailty assessment of liver transplant recipients with long term follow-up (>20 years): an ELITA/ELTR study
R. Viganò, A. Carvalho, A. Ferrarese, C. Becchetti, D.P. Bernasconi, F. Berardi, C. Di Benedetto, L. Pasulo, S. Jacobs, N. Sperduti, J. Ursic-Bedoya, A. Della Penna, L.M.A. Patetta, C. Mazzarelli, M. Cucco, M. Sagasta, M. Triolo, G. Vasta, A. Iozzi, G.P. Pageau, L. Gheorghe, V. Giannelli, S. Nadalin, P. Lampertico, S. Fagiuoli, G. Germani, M. Cesari, M. Berenguer, L.S. Belli
Milan, Valencia (Spain), Padoua, Monza, Rozzano (MI), Bergamo, Bucharest (Romania), Rome, Montpellier (France), Tübingen (Germany), Geneva (Switzerland)
63. Lymphoproliferative disorders following liver transplantation: a single center experience over 25 year
L. Pasulo, A. Barbui, R. Hakimizad, F. Leonardi, G. Mangia, P. Stroppa, M. Vigano’, S. Camagni, L. Licini, S. Fagiuoli
Bergamo, Milan
64. Assessment of sarcopenia in compensated liver cirrhosis by muscle ultrasound-based approach
R. Bonica, S. Como, A. Rizzo, M. Soresi, M. Pace, R. Chianetta, P. Cimino, R. Citarrella, L. Giannitrapani, M. Galia, A. Licata
Palermo
65. Burden of MASLD and impact of social determinants of health in an irregular migrant population
G. Di Franco, M. Soresi, T. Di Franco, G. Rizzo, M. Affronti, E. Piccione, A. Licata, M. Barbagallo, L. Giannitrapani
Palermo
66. Prothrombin induced by vitamin K absence-II (PIVKA-II) emerges as the strongest independent prognostic biomarker for hepatocellular carcinoma: a real-world multicenter study
F. Damone, G.P. Caviglia, P. Colombatto, F. Oliveri, M. Guariglia, G. Ricco, S. Gaia, V. Romagnoli, D. Cavallone, E. Rolle, P. Carucci, F. Faita, F. Bonino, M. R. Brunetto
Pisa, Turin
67. Radioembolization-Driven Downstaging in HCC: Five-Year Survival and Recurrence in Transplanted Patients
V. Giannelli, M. Spigaroli, C. Telesca, R. Cianni, G. Ventroni, N. Guglielmo, M. Colasanti, P. Riu, S. Demma, A. Pellicelli, G.M. Ettorre, G. Berardi
Rome
68. Effect of proton pump inhibitors exposure and discontinuation on infection outcomes in cirrhosis
A. Toscano, M.S. Franzè, C. Asero, G. Caccamo, R. Filomia, C. Pitrone, C. Saitta, I. Cacciola
Messina
69. AFP and PIVKA-II monthly dynamics in HCC patients undergoing locoregional and systemic therapies: implication for an earlier identification of responders
F. Damone, P. Colombatto, G. Ricco, F. Oliveri, V. Romagnoli, D. Cavallone, G. Petralli, F. Bonino, M.R. Brunetto
Pisa
70. Implementation of a multidisciplinary care pathway improves MASLD screening and cardiometabolic management
M. Cucco, R. De Maria, C. Pavanello, L. Cesarini, G. Mombelli, A. Alberti, F. Bertuzzi, L.S. Belli, L. Calabresi
Milan
71. Nutritional Status, Physical Activity, and Symptom Burden in Outpatients with Stable Polycystic Liver Disease
S. Di Cola, S. Khan, L. Lapenna, A. Vignone, V. Cardinale, M. Merli
Rome
72. Liver transplantation for acute liver failure in North Italy Transplant program area: clinical and epidemiological features over 35 years
C. Scalamogna, T. M. De Feo, M. . Donato, E. Sguazzini, R. Torelli, A. Longobardi, C. Dibenedetto, C. Quintini, E. Andorno, L. Pasulo, P. Stroppa, D. Pinelli, A. Lauterio, R. Viganò, U. Cillo, P. Burra, G. Conte, U. Baccarani, A. Carraro, M. Cardillo on Behalf of North Italy Transplant program (NITp) Liver and Intestine Transplant Working Group
Milan, Genoa, Bergamo, Padua, Ancona, Udine, Verona
73. Partial Splenic Embolization for the Prevention of Variceal Rebleeding in Patients Unsuitable for OLTx, TIPS, and Endovascular Treatment: Safety and Mortality
M. Bianchini, C. Gualandri, D. Saltini, T. Guasconi, A. Piscopo, G. Lo Cascio, A. S. Velasco Mayorga, F. Casari, G. Battinelli, F. Ascari, F. Prampolini, C. Caporali, F. Schepis
Modena
74. Lipidomic profiling of Metabolic dysfunction-Associated Steatohepatitis (MASH): identifying lipid biomarkers for detection and stratification of disease severity
F. Gabrielli, L. Bertarini, F. Pellati, P. Andreone, P. Ventura
Modena
75. Early Acute Rejection After Liver Transplantation in Patients Treated With Durvalumab: Preliminary Findings From the LIRICA and LITALHICA Protocols
E. Nieddu, A. Furlanetto, R. Romagnoli, D. Ghinolfi, S. Gruttadauria, A. Lauterio, A. Carraro, G.M. Ettorre, M. Vivarelli, M. Cescon, D. Pinelli, F. Di Benedetto, U. Baccarani, A.W. Avolio, G. Vennarecci, E. Rosso, C. Naldini, C. De Nardi, M. Botton, I. Billato, J. Lanari, M. Gambato, F. Bergamo, S. Trapani, G. Feltrin, C. Mescoli, G. De Conti, P. Burra, U. Cillo, E. Gringeri
Padua, Turin, Pisa, Palermo, Milan, Verona, Rome, Ancona, Bologna, Bergamo, Modena, Udine, Naples
76. Anti-HBc positivity is associated with worse tumour features and reduced survival in HBsAg-negative patients with hepatocellular carcinoma
M.S. Franzè, A. Toscano, C. Asero, G. Caccamo, R. Filomia, C. Pitrone, I. Cacciola, C. Saitta
Messina
77. Developing a Predictive Model of Prognosis After Curative-Intent Resection of Intrahepatic Cholangiocarcinoma
M. Botton, E. Nieddu, J. Lanari, A. Furlanetto, E. Rosso, C. Naldini, C. De Nardi, M. Polacco, D. Bassi, F. E. D’Amico, R. Boetto, A. Dolcet, A. Bertacco, A. Marchini, I. Billato, F. Bergamo, C. Soldà, M. D. Rizzato, S. Lonardi, C. Mescoli, U. Cillo, E. Gringeri
Padua
78. Revisiting national allocation policies for combined liver transplantation: time for acting
D. Pagano, A. Tropea, F. Di Francesco, S. Li Petri, P. Bonsignore, S. Calamia, I. Vitale, I. Vella, C. Accardo, A. Bertani, A. Galante, B. Buscemi, S. Gruttadauria
Palermo
79. Identification of a duodenal RNA signature in patients with MASLD-cirrhosis
F. Salomone, A. Scamporrino, A. Filippello, S. Piro, S. Di Mauro
Catania, Enna
80. Machine Learning Prediction of Liver Fibrosis in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease
S. Petta, G. Pennisi, C. Celsa, S. Messaoudi, E. Tsochatzis, E. Bugianesi, M. Yoneda, M. Zheng, H. Hagström, J. Boursier, J.L. Calleja, G.B. Goh, W. Chan, R. Gallego-Durán, A. J. Sanyal, V. de Lédinghen, P. N. Newsome, J. Fan, L. Castéra, M. Lai, C. Fournier-Poizat, G. L. Wong, A. Armandi, A. Nakajima, Y. Shang, M. de Saint-Loup, E. Llop, K.K.J. Teh, C. Lara-Romero, A. Asgharpour, M.S. Chan, M. Romero-Gomez, H. Lin, S. U. Kim, T.C. Yip, V. Calvaruso, J.C. Lai, B. Yang, H.W. Lee, G. Di Maria, M. Enea, S. Contino, V.W. Wong, G. Cirrincione, C. Cammà
Palermo, London (UK), Turin, Yokohama (Japan), Wenzhou (China), Stockholm (Sweden), Angers (France), Madrid (Spain), Singapore, Kuala Lumpur (Malaysia), Seville (Spain), Richmond (USA), Paris (France), Shanghai (China), Clichy (France), Boston (USA), Hong Kong (China), Birmingham (UK), Seoul (Republic of Korea), Amiens (France)